Home | About Me | Ross Mayfield | Brad Delong | Lawrence Lessig | Protein Folding Project | Edge | Gyre | Seed
Neurotechnology and Society
| November 2002 | ||||||
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| Oct Dec | ||||||
Friday, November 29, 2002Biosimulation will begin to transform the entire pharmaceutical value chain and the way governments determine the safety and efficacy of new drugs in years come. In silico biology is a logical compliment to traditional "wet lab" studies in test tubes (in vitro) and living organisms (in vivo). Currently companies are using biosimulation to narrow potential compounds down more quickly. As data generated from the Whole Biochip becomes available doctors will be able to simulate different compounds in real-time to see their potential effects in patients. As biosimulation becomes more robust, the FDA will begin to mandate simulation-based screening of therapeutic agents, just as plans for all high-rise buildings are required to undergo structural dynamics analysis to confirm earthquake resistance today. Biosimulation has the potential to cut years off the development and approval process.
3:31:34 PM
comment []
This Page was last update: 12/2/2002; 6:36:23 PM
Copyright 2002 Zack Lynch
Theme Design by Bryan Bell
